AnaptysBio Announces Appointment of John Orwin as Chairman of the Board of Directors
September 18, 2023 16:15 ET
|
AnaptysBio, Inc.
After more than 15 years serving on AnaptysBio’s Board of Directors, Jamie Topper, M.D., Ph.D., is stepping down and will serve as an advisor to the Board through Q1 2024 SAN DIEGO, Sept. 18, 2023...
AnaptysBio to Present at the Stifel 2023 Immunology and Inflammation Virtual Summit
September 12, 2023 09:15 ET
|
AnaptysBio, Inc.
SAN DIEGO, Sept. 12, 2023 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that...
AnaptysBio Announces Second Quarter 2023 Financial Results and Provides Business Update
August 07, 2023 16:15 ET
|
AnaptysBio, Inc.
Completed enrollment of the GEMINI-1 Phase 3 trial for imsidolimab (IL-36R) in generalized pustular psoriasis (GPP) and anticipate top-line data in Q4 2023Initiating a global Phase 2b trial for...
AnaptysBio- and GSK-Partnered Immuno-Oncology Agent JEMPERLI (dostarlimab-gxly) plus Chemotherapy Approved in the U.S. for dMMR/MSI-H Primary Advanced or Recurrent Endometrial Cancer
July 31, 2023 13:34 ET
|
AnaptysBio, Inc.
JEMPERLI is the first immuno-oncology treatment approved in the frontline setting for this patient population in combination with chemotherapyU.S. Food and Drug Administration approval represents a...
AnaptysBio Announces Participation in Upcoming Investor Conferences
May 30, 2023 16:15 ET
|
AnaptysBio, Inc.
SAN DIEGO, May 30, 2023 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that...
AnaptysBio Announces First Quarter 2023 Financial Results and Provides Pipeline Update
May 11, 2023 16:15 ET
|
AnaptysBio, Inc.
Initiated a global Phase 2b trial to treat atopic dermatitis with ANB032, a BTLA agonistHosting a virtual BTLA Agonist (ANB032) R&D Event on May 25, 2023Announced International Societies for...
AnaptysBio Announces British Journal of Dermatology Publication of Imsidolimab (IL-36R) Previously Reported Phase 2 GALLOP Data in Generalized Pustular Psoriasis (GPP)
May 02, 2023 09:15 ET
|
AnaptysBio, Inc.
Rapid and sustained efficacy demonstrated in GPP patients after only a single dose, achieving primary endpoint at Week 4Flare control sustained on monthly subcutaneous doses through Week 16Imsidolimab...
AnaptysBio Announces Appointment of Rita Jain, M.D., to Board of Directors
April 06, 2023 16:15 ET
|
AnaptysBio, Inc.
SAN DIEGO, April 06, 2023 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced the...
AnaptysBio- and GSK-partnered immuno-oncology agent Jemperli (dostarlimab-gxly) plus chemotherapy demonstrates statistically significant and clinically meaningful improvement in progression-free survival for the treatment of primary advanced or recurrent endometrial cancer versus chemotherapy alone in Phase 3 RUBY trial
March 27, 2023 18:50 ET
|
AnaptysBio, Inc.
Results published in The New England Journal of Medicine and presented simultaneously at ESMO Virtual Plenary and SGO Annual Meeting72% and 36% reduction in the risk of disease progression or death...
AnaptysBio Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
March 01, 2023 16:05 ET
|
AnaptysBio, Inc.
Initiating a global Phase 2b trial for rosnilimab (PD-1 agonist) to treat rheumatoid arthritis anticipated Q3 2023Initiating a global Phase 2b trial for ANB032 (BTLA agonist) to treat atopic...